Novartis’ Ionis-partnered drug designed to lower levels of Lp (a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular events ...
Please provide your email address to receive an email when new articles are posted on . Lp(a) is a highly atherogenic particle with no available targeted therapeutics. Screening and targeting ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results